Skip to content
For research use only. Not for human or veterinary use. Not a drug, food, or dietary supplement.
AMIRAVOResearch Library
Cycle-length evidence

Eloralintide cycle length: what human studies ran

InvestigationalAHuman trial evidence
Short answer: there is no established Eloralintide cycle length or break. The human studies below ran for set periods under monitoring; none tested repeated courses.

Treatment and follow-up in human studies

  1. Phase 2: 48 weeks of once-weekly treatment 1. Multiple-ascending-dose study: 12 weeks of dosing followed by a 10-week follow-up (about 22 weeks overall) 2. Single-ascending-dose study: one dose with follow-up visits to day 29 and a safety visit on day 60 3. ENLIGHTEN-1 and -2: primary endpoint at week 64 5,6.

What has not been tested

  • On-and-off schedules or breaks between courses.
  • Repeated courses and long-term exposure beyond the periods listed.
  • Eloralintide combined with other compounds, unless a study above says so.

Frequently asked questions

Is there an established Eloralintide cycle length?
No. Human studies administered Eloralintide for the periods listed on this page. Those are study durations; none tested an on-and-off schedule or a break.
What is the longest human study of Eloralintide?
The durations are listed on this page with their sources; compare them directly rather than relying on a summary.
Do study durations tell me how long to use something?
No. A study duration is how long investigators administered a compound to selected participants under monitoring. It is not a recommended course, and a break between courses has not been tested for any compound on this site that is not approved.
Eloralintide dosing reference Full research page

References

  1. Eloralintide, a selective amylin receptor agonist for the treatment of obesity: a 48-week phase 2, multicentre, double-blind, randomised, placebo-controlled trial Lancet. 2025
  2. Eloralintide, a selective, long-acting amylin receptor agonist for treatment of obesity: Phase 1 proof of concept Diabetes Obes Metab. 2026
  3. Eloralintide (LY3841136), a novel amylin receptor agonist for the treatment of obesity: From discovery to clinical proof of concept Mol Metab. 2025
  4. A Study of LY3841136 Compared With Placebo in Adult Participants With Obesity or Overweight (NCT06230523) ClinicalTrials.gov. 2024
  5. ENLIGHTEN-1: A Study of Eloralintide (LY3841136) in Participants With Obesity, or Overweight Without Type 2 Diabetes (NCT07321886) ClinicalTrials.gov. 2026
  6. ENLIGHTEN-2: A Study of Eloralintide (LY3841136) in Participants With Obesity or Overweight, and Type 2 Diabetes (NCT07282600) ClinicalTrials.gov. 2025
  7. AMPLIFY-1: A Study of EloraTZP in Adult Participants With Obesity Without Type 2 Diabetes (NCT07881432) ClinicalTrials.gov. 2026
  8. Drugs@FDA application data queried through openFDA for eloralintide (no matching application record returned on 22 October 2026) openFDA / Drugs@FDA. 2026
  9. PubChem compound record for eloralintide (CID 175663130) PubChem. 2026
  10. World Anti-Doping Agency International Standard Prohibited List 2026 WADA. 2026
  11. WEGOVY (semaglutide) injection, prescribing information (section 5.8, heart rate increase) FDA label via DailyMed. 2024